Literature DB >> 12391121

Targeted disruption of the Fgf2 gene does not affect vascular growth in the mouse ischemic hindlimb.

Chris J Sullivan1, Thomas Doetschman, James B Hoying.   

Abstract

Ischemic revascularization involves extensive structural adaptation of the vasculature, including both angiogenesis and arteriogenesis. Previous studies suggest that fibroblast growth factor (FGF)-2 participates in both angiogenesis and arteriogenesis. Despite this, the specific role of endogenous FGF-2 in vascular adaptation during ischemic revascularization is unknown. Therefore, we used femoral artery ligation in Fgf2(+/+) and Fgf2(-/-) mice to test the hypothesis that endogenous FGF-2 is an important regulator of angiogenesis and arteriogenesis in the setting of hindlimb ischemia. Femoral ligation increased capillary and arteriole density in the ischemic calf in both Fgf2(+/+) and Fgf2(-/-) mice. The level of angiographically visible arteries in the thigh was increased in the ischemic hindlimb in all mice, and no significant differences were observed between Fgf2(+/+) and Fgf2(-/-) mice. Additionally, limb perfusion progressively improved to peak values at day 35 postsurgery in both genotypes. Given the equivalent responses observed in Fgf2(+/+) and Fgf2(-/-) mice, we demonstrate that endogenous FGF-2 is not required for revascularization in the setting of peripheral ischemia. Vascular adaptation, including both angiogenesis and arteriogenesis, was not affected by the absence of FGF-2 in this model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12391121      PMCID: PMC3872060          DOI: 10.1152/japplphysiol.00451.2002

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  33 in total

1.  Fibroblast growth factor-2 selectively stimulates angiogenesis of small vessels in arterial tree.

Authors:  P Parsons-Wingerter; K E Elliott; J I Clark; A G Farr
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

2.  Disruption of the fibroblast growth factor-2 gene results in decreased bone mass and bone formation.

Authors:  A Montero; Y Okada; M Tomita; M Ito; H Tsurukami; T Nakamura; T Doetschman; J D Coffin; M M Hurley
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

3.  Compensation by fibroblast growth factor 1 (FGF1) does not account for the mild phenotypic defects observed in FGF2 null mice.

Authors:  D L Miller; S Ortega; O Bashayan; R Basch; C Basilico
Journal:  Mol Cell Biol       Date:  2000-03       Impact factor: 4.272

4.  Time course of arteriogenesis following femoral artery occlusion in the rabbit.

Authors:  I E Hoefer; N van Royen; I R Buschmann; J J Piek; W Schaper
Journal:  Cardiovasc Res       Date:  2001-02-16       Impact factor: 10.787

5.  Fibroblast growth factor-2 mediates pressure-induced hypertrophic response.

Authors:  J E Schultz; S A Witt; M L Nieman; P J Reiser; S J Engle; M Zhou; S A Pawlowski; J N Lorenz; T R Kimball; T Doetschman
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

6.  Basic fibroblast growth factor is neither necessary nor sufficient for the development of retinal neovascularization.

Authors:  H Ozaki; N Okamoto; S Ortega; M Chang; K Ozaki; S Sadda; M A Vinores; N Derevjanik; D J Zack; C Basilico; P A Campochiaro
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

Review 7.  Clinical trials in coronary angiogenesis: issues, problems, consensus: An expert panel summary.

Authors:  M Simons; R O Bonow; N A Chronos; D J Cohen; F J Giordano; H K Hammond; R J Laham; W Li; M Pike; F W Sellke; T J Stegmann; J E Udelson; T K Rosengart
Journal:  Circulation       Date:  2000-09-12       Impact factor: 29.690

8.  Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain.

Authors:  T Yamashita; M Yoshioka; N Itoh
Journal:  Biochem Biophys Res Commun       Date:  2000-10-22       Impact factor: 3.575

9.  Regulation of new blood vessel growth into ischemic skeletal muscle.

Authors:  R L Bush; W C Pevec; A Ndoye; A T Cheung; J Sasse; D N Pearson
Journal:  J Vasc Surg       Date:  1998-11       Impact factor: 4.268

10.  Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model.

Authors:  T Tobe; S Ortega; J D Luna; H Ozaki; N Okamoto; N L Derevjanik; S A Vinores; C Basilico; P A Campochiaro
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

View more
  14 in total

1.  Cx40 is required for, and cx37 limits, postischemic hindlimb perfusion, survival and recovery.

Authors:  Jennifer S Fang; Stoyan N Angelov; Alexander M Simon; Janis M Burt
Journal:  J Vasc Res       Date:  2011-10-04       Impact factor: 1.934

Review 2.  Microvascular repair: post-angiogenesis vascular dynamics.

Authors:  Amanda J LeBlanc; Laxminarayanan Krishnan; Christopher J Sullivan; Stuart K Williams; James B Hoying
Journal:  Microcirculation       Date:  2012-11       Impact factor: 2.628

3.  Compromised regulation of tissue perfusion and arteriogenesis limit, in an AT1R-independent fashion, recovery of ischemic tissue in Cx40(-/-) mice.

Authors:  Jennifer S Fang; Stoyan N Angelov; Alexander M Simon; Janis M Burt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-01-04       Impact factor: 4.733

4.  Cx37 deletion enhances vascular growth and facilitates ischemic limb recovery.

Authors:  Jennifer S Fang; Stoyan N Angelov; Alexander M Simon; Janis M Burt
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-08-19       Impact factor: 4.733

5.  Implanted microvessels progress through distinct neovascularization phenotypes.

Authors:  Sara S Nunes; Kevin A Greer; Chad M Stiening; Helen Y S Chen; Kameha R Kidd; Mark A Schwartz; Chris J Sullivan; Harish Rekapally; James B Hoying
Journal:  Microvasc Res       Date:  2009-10-13       Impact factor: 3.514

6.  Gene targeted ablation of high molecular weight fibroblast growth factor-2.

Authors:  Mohamad Azhar; Moying Yin; Ming Zhou; Hongqi Li; Marwan Mustafa; Eyad Nusayr; Jack B Keenan; Hwudaurw Chen; Sharon Pawlosky; Connie Gard; Christina Grisham; L Philip Sanford; Tom Doetschman
Journal:  Dev Dyn       Date:  2009-02       Impact factor: 3.780

Review 7.  Branching morphogenesis and antiangiogenesis candidates: tip cells lead the way.

Authors:  Peter Carmeliet; Frederik De Smet; Sonja Loges; Massimiliano Mazzone
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

Review 8.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

9.  Testing clinical therapeutic angiogenesis using basic fibroblast growth factor (FGF-2).

Authors:  Ronnier J Aviles; Brian H Annex; Robert J Lederman
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

10.  Structural remodeling of the mouse gracilis artery: coordinated changes in diameter and medial area maintain circumferential stress.

Authors:  Gabriel Gruionu; James B Hoying; Axel R Pries; Timothy W Secomb
Journal:  Microcirculation       Date:  2012-10       Impact factor: 2.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.